Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Above 50-Day Moving Average - Here's Why

Key Points

• Fennec Pharmaceuticals stock price has crossed above its 50-day moving average, trading at C$11.93 compared to the average of C$11.89.
• The company's quick ratio is 10.17, while it has a market cap of C$332.04 million and a debt-to-equity ratio of -620.83.
• Insider Rostislav Christov Raykov sold 10,000 shares at C$11.71, indicating that insiders have sold a total of 13,246 shares worth $137,297 in the last quarter.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$11.89 and traded as high as C$12.20. Fennec Pharmaceuticals shares last traded at C$11.93, with a volume of 1,370 shares.

Fennec Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The firm has a market capitalization of C$336.21 million, a price-to-earnings ratio of -26.84 and a beta of 2.09. The business's fifty day simple moving average is C$11.89 and its 200 day simple moving average is C$10.42.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,000 shares of the firm's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of C$11.71, for a total value of C$117,096.00. Insiders have sold 13,246 shares of company stock valued at $137,297 in the last ninety days. Company insiders own 16.20% of the company's stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.